A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

NCT03232593 · clinicaltrials.gov ↗

COMPLETED

Status

1758

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma
Carcinoma, Non-Small Cell Lung
Small Cell Lung Carcinoma
Triple Negative Breast Carcinoma
Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab

Sponsor

Hoffmann-La Roche